SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals

Nat Commun. 2024 Apr 9;15(1):3077. doi: 10.1038/s41467-024-47429-8.

Abstract

Knowledge is limited as to how prior SARS-CoV-2 infection influences cellular and humoral immunity after booster-vaccination with bivalent BA.4/5-adapted mRNA-vaccines, and whether vaccine-induced immunity may indicate subsequent infection. In this observational study, individuals with prior infection (n = 64) showed higher vaccine-induced anti-spike IgG-antibodies and neutralizing titers, but the relative increase was significantly higher in non-infected individuals (n = 63). In general, both groups showed higher neutralizing activity towards the parental strain than towards Omicron-subvariants BA.1, BA.2 and BA.5. In contrast, CD4 or CD8 T cell levels towards spike from the parental strain and the Omicron-subvariants, and cytokine expression profiles were similar irrespective of prior infection. Breakthrough infections occurred more frequently among previously non-infected individuals, who had significantly lower vaccine-induced spike-specific neutralizing activity and CD4 T cell levels. In summary, we show that immunogenicity after BA.4/5-bivalent vaccination differs between individuals with and without prior infection. Moreover, our results may help to improve prediction of breakthrough infections.

Publication types

  • Observational Study

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Breakthrough Infections
  • COVID-19* / prevention & control
  • Humans
  • Immunity, Humoral
  • SARS-CoV-2*
  • Vaccination
  • Vaccines, Combined

Substances

  • Vaccines, Combined
  • Antibodies, Neutralizing
  • Antibodies, Viral